FindTrial
Sign In

Measurement of blood levels of imatinib to predict early response to treatment in patients with chronic myeloid leukemia

Study of trough plasma imatinib levels and its correlation with early responses in Chronic Myeloid leukemia in chronic phase.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/01/011356
Enrollment
50
Registered
2018-01-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Myeloid Leukemia

Interventions

None listed

Sponsors

Tata Memorial Hospital Mumbai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Chronic Myeloid Leukemia in chronic phase Age more than 18 years

Exclusion criteria

Exclusion criteria: 1. Patients on concurrent medications affecting imatinib drug levels 2. Patients who have been priorly treated outside with Imatinib before referral to our institute 3. Patients in whom compliance is not assured 4. Patients in accelerated phase or blast crisis of chronic myeloid leukemia as per the WHO definition

Design outcomes

Primary

MeasureTime frame
Correlation of trough plasma imatinib levels with three month molecular responsesTimepoint: 3 months—

Secondary

MeasureTime frame
Correlation of trough plasma imatinib levels with three month molecular responsesTimepoint: 6 months—

Countries

India

Contacts

Public ContactHari Menon

Tata Memorial Hospital

menontata@yahoo.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026